Introduction
Heart failure in humans is characterized by abnormalities of relaxation and intracellular Ca2+ handling that may reflect changes in the uptake of Ca2+ by sarcoplasmic reticulum (1, 2) . We previously measured unstimulated Ca2+ uptake in sarco-plasmic reticulum from normal and failing human left ventricles, and found no differences in steady state kinetic parameters (3) . Recent studies in animal models, however, have provided evidence that the pathophysiology of heart failure may involve changes in the regulation of Ca2" uptake associated with phospholamban phosphorylation. In hyperthyroidism, a decrease in the ratio of phospholamban to Ca2"-transporting ATPase in cardiac sarcoplasmic reticulum has been reported, with corresponding changes in messenger RNA levels for the two proteins (4, 5) . These changes could account for the decreased sensitivity of relaxation rates to ,3-adrenergic stimulation in this condition (6) (7) (8) . In contrast, myocardial hypertrophy induced by pressure load was accompanied by parallel decreases in messenger RNA levels for the two proteins (5) . Phospholamban levels were also diminished in sarcoplasmic reticulum from rats treated with chronic infusions of isoproterenol (9) . On the other hand, phospholamban-mediated stimulation of Ca2" uptake has never been demonstrated in human cardiac sarcoplasmic reticulum, and in one study the magnitude of cAMP-dependent phosphate incorporation into human cardiac sarcoplasmic reticulum was only one-fourth that observed in canine preparations (10) . The relative significance of phospholamban-mediated stimulation in humans is thus unclear.
In view of these considerations, we sought to measure the magnitude of phospholamban-mediated stimulation of Ca2" uptake in human cardiac sarcoplasmic reticulum, and to determine whether heart failure in humans involves changes in the relative levels of the two proteins that result in changes in phospholamban-mediated stimulation of Ca2" uptake. In Vma., KO.5 ([Ca2+] at which activity was half-maximal) and nH0J (Hill coefficient with respect to Ca2") for unstimulated Ca2`uptake were 593±82 nmol/mg-min, 0.68±0.07 gM and 1.7±0.1 in the preparations from normal hearts and 593±36 nmol/mg-min, 0.63±0.03 and 1.6±0.1 in the preparations from failing hearts. The sarcoplasmic reticulum used in the experiments represented by Figs. 1-3 and Table I was prepared from myocardial specimens combined from three excised failing hearts. Canine cardiac sarcoplasmic reticulum was prepared as described previously (I 1).
Measurement of Ca2`uptake. Ca2+ uptake in human and canine sarcoplasmic reticulum was assayed using an adaptation of our previously published methods (3, 11, 12 (15) . Kma,0.5, and nH were calculated from uptake rates as described previously (3) .
To measure the effect of anti-phospholamban monoclonal antibody (prepared and characterized as previously reported, reference 12) on Ca2+ uptake, sarcoplasmic reticulum was incubated with antibody in the above reaction mixture for 5 min at 37°C before initiation of uptake by addition of ATP. To measure the effect of phosphorylation of phospholamban on Ca2+ uptake, phosphorylation of sarcoplasmic reticulum vesicles was allowed to proceed in the absence of oxalate as described below (using unlabeled ATP) for 2 min. Ca2l uptake was then initiated by addition of a solution containing oxalate, 45CaC12, EGTA, KC1, MgCl2, and MOPS such that the final content of the reaction mixture was identical to that described above.
Phosphorylation ofphospholamban. The method is derived from procedures previously described (10) . Cardiac sarcoplasmic reticulum was suspended in the absence or presence ofcAMP-dependent protein kinase (prepared from bovine heart according to Peters et Aliquots were heated at 95°C for S min before electrophoresis through 0.1% SDS/7.5-20% polyacrylamide gels (17) . Phospholamban bands were identified by autoradiography and excised. Phosphate incorporation in excised bands was determined by scintillation spectrometry and normalized to total sarcoplasmic reticulum protein per lane. absence of specified
[Antibody], (mg/mi) concentrations of antibody, after which uptake was measured at 0.2 MM Ca2+. Each value is the mean±standard error of three to six assays. concentration of 0.05 mg/ml (the ratio of antibody to sarcoplasmic reticulum protein was 0.5 mg/mg), with no further stimulation at higher antibody concentrations. No stimulation of uptake was seen when the antibody was denatured by heating at 95°C for 10 min before addition, and no stimulation was seen in the presence of monoclonal antibodies directed against nonsarcoplasmic reticulum proteins.
We compared these effects with those associated with phosphorylation of phospholamban by cAMP-dependent protein kinase. Phosphate incorporation into phospholamban was measured after incubation of sarcoplasmic reticulum for 2 and 5 min at concentrations of cAMP-dependent protein kinase ranging from 0.2 to 2.0 ,M (Fig. 2) . Phosphate incorporation reached its maximal level of 0.31±0.05 nmol/mg after 5 min incubation in the presence of 1.0 uM cAMP-dependent protein kinase. Maximal phosphate incorporation was not increased by the addition of higher concentrations of protein kinase, extension of the incubation time, or inhibition of phosphatase activity with 10 mM NaF. We then examined the effects of cAMP-dependent phosphorylation on Ca2+ uptake in human cardiac sarcoplasmic reticulum. Stimulation ofCa2" uptake at 0.2 uM Ca2" reached a level of 2.40-fold after incubation in the presence of 0.6 MM cAMP-dependent protein kinase, with no further stimulation at higher kinase concentrations. The magnitude of this stimulation was indistinguishable from that of stimulation by anti-phospholamban monoclonal antibody.
Effect of anti-phospholamban monoclonal antibody on steady state kinetics of Cad2 uptake. The above experiments confirmed that, in human as in bovine cardiac sarcoplasmic reticulum, stimulation ofCa2" uptake by anti-phospholamban monoclonal antibody resembles stimulation resulting from cAMP-dependent phosphorylation. We proceeded to characterize the effects of this antibody on the steady state kinetics of
Results
Stimulation of Ca2l uptake in human cardiac sarcoplasmic reticulum by anti-phospholamban monoclonal antibody. In bovine cardiac sarcoplasmic reticulum, stimulation of Ca2+ uptake by anti-phospholamban monoclonal antibody had been shown to be identical to stimulation by cAMP-dependent phosphorylation (12) . To determine whether this were true in human preparations, we examined the effect of antiphospholamban monoclonal antibody on Ca2+ uptake by human cardiac sarcoplasmic reticulum (Fig. 1) Values are derived as described in Methods from the data represented in Fig. 3 . stimulated Ca2l uptake by an identical factor in preparations from the normal and failing hearts.
Discussion
In 1986, Suzuki and Wang reported the preparation of a monoclonal antibody to canine and bovine cardiac phospholamban (12) . This antibody was shown to bind to a site at or near the amino acid side chain phosphorylated by cAMP-dependent and calmodulin-dependent protein kinases, and binding resulted in stimulation of Ca2+ uptake quantitatively identical to that accompanying cAMP-dependent phosphorylation. In the present study, we have confirmed that this antibody has similar effects in human preparations. Measurement of Ca2+ uptake by sarcoplasmic reticulum in the presence and absence of this antibody provides a simple assay sensitive to changes in both the relative level of phospholamban and its coupling to the Ca2+-transport mechanism. The simplicity and reproducibility of this procedure made it possible for us to test our hypotheses using limited amounts of human myocardial tissue. Our experimental conditions were designed to approximate those expected to occur physiologically. Under these conditions, phospholamban-mediated stimulation of steady state Ca2+ uptake in human cardiac sarcoplasmic reticulum resulted from an increase in the affinity of the Ca2+-transporting ATPase for Ca2+, with no significant change in maximal turnover rate or cooperativity. Stimulation of Ca2+ uptake was therefore profound at 0.2 MM Ca2+, a value in the range expected to occur during diastole, but much less impressive at the higher Ca2+ concentrations expected to occur during systole (18) . These observations may have important implications It has been shown that phospholamban in its unphosphorylated conformation inhibits Ca2+ uptake activity, and that phosphorylation relieves this inhibition (19, 20) . Recent studies suggest that neutralization of the positive charges on phospholamban's cytoplasmic amino acid side chains has similar stimulatory effects on Ca>2 uptake (21) , and the effects of phosphorylation as well as anti-phospholamban monoclonal antibody could be compatible with such a mechanism. The nature and magnitude of phospholamban-mediated effects in human cardiac sarcoplasmic reticulum were similar to those observed in canine preparations. These results were somewhat surprising in view ofa prior study in which phosphate incorporation was fourfold higher in canine than in human preparations (10) , since the essentially identical stimulation we observed would suggest that relative levels and coupling of phospholamban and the Ca2+-transporting ATPase are similar in the two systems. The measurements made in the prior study relied on crude membrane preparations from diverse species, and it is possible that these preparations differed with respect to relative purity and efficiency of phosphorylation. Recent studies in animal models of thyroid disease, pressure-load hypertrophy and chronic fl-adrenergic stimulation have raised the possibility that heart failure may involve abnormalities in the transcription and translation of phospholamban and the Ca2l-transporting ATPase, affecting the levels of these proteins in sarcoplasmic reticulum (4, 5, 9) . Were such mechanisms pathogenetic in idiopathic dilated cardiomyopathy in humans, changes in basal Ca2> uptake or its phospholamban-mediated stimulation would have been predicted. Our previous studies showed no differences in basal Ca2+ uptake in this condition. The present experiments extend those studies, and demonstrate that phospholamban-mediated stimulation of uptake is similarly unaffected in this condition. In view of these findings, it is interesting to note that basal Ca2+ uptake rates are depressed in a hereditary dilated cardiomyopathy in Syrian hamsters (22) . Taken together, these observations suggest that animal models of heart disease may not be representative of the pathophysiology of heart failure in humans. It remains possible that abnormal relaxation in heart failure occurs via mechanisms involving phospholamban-mediated stimulation. The decreased j3-adrenergic responsiveness observed in chronic heart failure in humans might lead in turn to decreased intracellular cAMP concentrations, decreased phosphorylation of phospholamban, decreased stimulation of Ca>' uptake by sarcoplasmic reticulum, and increased end-diastolic Ca2l concentrations (23) . Our results do not exclude the possibility that abnormalities in other sarcoplasmic reticulum proteins involved in Ca2+ storage and release or in the amount of sarcoplasmic reticulum relative to contractile elements are involved in human disease. We would also emphasize that our conclusions apply only to idiopathic dilated cardiomyopathy, and should not be generalized to other forms of heart failure.
